Two key House Democrats are opening a joint committee investigation into Biogen Inc.’s new Alzheimer’s drug, saying its approval and high cost create questions about the regulatory process.
Two key House Democrats are opening a joint committee investigation into Biogen Inc.’s new Alzheimer’s drug, saying its approval and high cost create questions about the regulatory process.